LBRX
$24.86-1.60 (-6.07%)
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in...
Recent News
LB Pharmaceuticals initiates Phase 2 trial of LB-102
LB Pharmaceuticals (LBRX) announced the initiation of a Phase 2 trial evaluating the efficacy and safety of LB-102 in patients with bipolar depression. LB-102, a novel, once-daily, oral investigational small molecule, is a potent and selective antagonist of D2, D3, and 5HT7 receptors that is being advanced as a potential first benzamide antipsychotic in the U.S. for the treatment of neuropsychiatric disorders. Anna Eramo, Chief Medical Officer of LB Pharmaceuticals added, “We believe LB-102’s ph
LB Pharmaceuticals Inc.: Q3 Earnings Snapshot
NEW YORK (AP) — LB Pharmaceuticals Inc. LBRX) on Thursday reported a loss of $3.6 million in its third quarter. On a per-share basis, the New York-based company said it had a loss of 61 cents.
Crunching the numbers on this week's IPO performances
Gemini Space Station (GEMI) and Black Rock Coffee Bar (BRCB) will begin publicly trading on Friday, adding to the growing list of IPOs in 2025 and joining the ranks of Klarna (KLAR), Figure Technology Solutions (FIGR), Chime Financial (CHYM), Figma (FIG), CoreWeave (CRWV), Circle Internet Group (CRCL), Bullish (BLSH), Firefly Aerospace (FLY), and eToro (ETOR). Yahoo Finance markets and data editor Jared Blikre looks back at this week's top IPOs and how these companies' stocks are stacking up to their opening prices. Catch Yahoo Finance's full interviews with Klarna co-founder and CEO Sebastian Siemiatkowski, Figure co-founder and executive chairman Mike Cagney, and Gemini COO Marshall Beard after their companies' respective IPO launches this week. To watch more expert insights and analysis on the latest market action, check out more Market Domination.
LB Pharmaceuticals raises $285 million in US IPO
The New York-based firm sold 19 million shares at $15 each, within its marketed range of $14 to $16 apiece. The IPO valued LB at $301.5 million. Companies ranging from crypto to consumer are poised to list their shares on U.S. exchanges this week as the U.S. IPO market makes a resurgent comeback, with investors shrugging off tariff concerns that scuttled all dealmaking in April.
LB Pharmaceuticals eyes $322 million valuation in biotech IPO amid sector drought
Weight-loss drug developer Aardvark Therapeutics was the last notable biotech to raise more than $50 million in 2025; its shares have nearly halved since their February debut. Aurion Biotech and Odyssey Therapeutics have both scrapped planned New York listings earlier this year. Founded in 2015, LB Pharmaceuticals is developing therapies that target schizophrenia, bipolar depression, and other neuropsychiatric diseases.